Composition with high dispersibility for uric acid reduction as well as a solid drink

Abstract

A composition with high dispersibility for lowering uric acid levels, characterized in that the composition comprises a uric acid-lowering active ingredient and a dispersing agent, wherein the uric acid-lowering active ingredient contains vine tea extract and Cordyceps militaris extract and the dispersing agent is a sugar alcohol; based on the dry mass, the composition contains 1.5 to 2.5 parts by mass of vine tea extract and 0.5 to 1.5 parts by mass of Cordyceps militaris extract.

Description

TECHNICAL AREA

[0001] The utility model relates to the technical field of pharmaceuticals and foodstuffs, in particular a composition with high dispersibility for lowering uric acid levels and a solid beverage. State of the art

[0002] Hyperuricemia (HUA) is a metabolic disorder caused by increased uric acid production and / or decreased uric acid excretion due to impaired purine metabolism in the body. Internationally, the diagnosis of hyperuricemia is defined as follows: On a normal purine diet, the fasting blood uric acid level is above 420 µmol / L in men and above 360 ​​µmol / L in women on two non-consecutive days. The latest edition of the "Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout (2019)" defines: Regardless of sex, a condition is considered hyperuricemia if the blood uric acid level is above 420 µmol / L on two non-consecutive days.

[0003] Prolonged hyperuricemia can not only trigger gouty arthritis, lead to joint deformities and kidney dysfunction, but is also closely linked to the development and progression of cardiovascular diseases such as hypertension, diabetes mellitus, and arteriosclerosis. It has become one of the most common chronic diseases, posing a serious threat to public health.

[0004] Currently, first-line clinical drugs for lowering uric acid levels mainly include allopurinol and febuxostat to inhibit uric acid production, and benzbromarone to promote uric acid excretion. However, long-term use of these chemical drugs is frequently associated with side effects such as liver and kidney damage, gastrointestinal reactions, and hypersensitivity reactions, which limits their long-term use in some patients, particularly those with asymptomatic hyperuricemia. Therefore, the search for safe, effective, and suitable long-term functional uric acid-lowering products derived from natural substances has become a key research focus in this field.

[0005] Vine tea consists of the young stems and leaves of Ampelopsis grossedentata (Hand.-Mazz.) WTWang, first mentioned in the "Classic of Tea," and belongs to the perennial woody climbing plants of the genus Ampelopsis in the family Vitaceae. Vine tea is both medicinal and edible; the use of its young stems and leaves as a tea in folk tradition has a history of several hundred years. According to literature such as the "Collection of Chinese Herbal Remedies," vine tea, when used medicinally, has the effect of clearing heat and releasing toxins, and can treat wind-related heat-related colds, sore throats, swellings, etc.Modern studies show that vine tea and its extracts are rich in flavonoids, with the highest content of dihydromyricetin, and that it has numerous pharmacological effects such as anti-inflammatory, antibacterial, antioxidant, blood sugar lowering, blood lipid lowering and blood pressure lowering effects.

[0006] Cordyceps sinensis is an extremely valuable Chinese herbal remedy with high medicinal value; however, its natural resources are scarce, its price is high, and its cultivation is difficult. Cordyceps militaris, also known as northern Cordyceps sinensis, belongs to the phylum Ascomycota, the order Hypocreales, and the family Clavicipitaceae. Although Cordyceps militaris belongs to the same genus as Cordyceps sinensis but to a different species, studies have shown that their biologically active ingredients are similar. Furthermore, research indicates that Cordyceps militaris is rich in various nutrients such as cordycepin, cordyceps polysaccharide, cordycepic acid, and amino acids, and exhibits pharmacological effects including antitumor, immunoregulatory, anti-inflammatory, and antioxidant properties.Artificial cultivation and industrialization have now been achieved, so that Cordyceps militaris can serve as an effective substitute for Cordyceps sinensis.

[0007] Rosa roxburghii Tratt, also known as Silken Rose, Spring Farewell Rose, Wenxian Fruit, etc., is a perennial, deciduous, bushy shrub of the genus Rosa in the family Rosaceae, native primarily to southwestern China. Rosa roxburghii is rich in constituents such as flavonoids, vitamin C, superoxide dismutase (SOD), polysaccharides, polyphenols, and triterpenoids. It contains an average of 920 mg of flavonoids, 1300–3500 mg of vitamin C, and 13,000 SOD activity units per 100 g of Rosa roxburghii, which is why it is considered the "Queen of Fruits." The "Caomu Bianfang" (a classic herbal) also records that the leaves of Rosa roxburghii can be used to treat scabies, abscesses, and metal wounds.Current pharmacological studies show that preparations made from Rosa roxburghii have pharmacological effects such as antioxidant, tumor-inhibiting, anti-atherosclerotic and blood sugar-lowering effects.

[0008] Although the pharmacological effects of the aforementioned vine tea, Cordyceps militaris, and Rosa roxburghii have been extensively researched, there is no prior art publication on the scientific combination of these three to achieve a synergistic effect in lowering blood uric acid levels in patients with hyperuricemia. Furthermore, practical application scenarios, particularly when the composition is intended as a liquid preparation such as an orally administered solution or as a ready-to-use beverage, reveal poor solubility during the dissolving or infusion process. Due to the presence of saponins and other constituents, a large amount of foam is frequently produced. As a powder for preparation, it exhibits slow dispersion, which negatively impacts the user experience and taste.Therefore, the development of a new composition that both effectively lowers blood uric acid levels and has excellent dispersibility is of great clinical importance and market prospects. CONTENTS OF THE INSTRUCTION MANUAL

[0009] The purpose of the utility model is to provide, in view of at least one deficiency in the prior art, a composition with high dispersibility for lowering uric acid and a solid drink to solve the technical problems existing in the related technology, such as the lack of uric acid lowering products with natural, safe and effective ingredients suitable for long-term use, as well as the bad taste and poor solubility of the uric acid lowering products.

[0010] To achieve the aforementioned purposes, the utility model employs the following technical solution:

[0011] A first aspect of the utility model is the provision of a highly dispersible composition for lowering uric acid levels, wherein the composition comprises a uric acid-lowering active ingredient and a dispersion-enhancing substance. The uric acid-lowering active ingredient comprises extract of vine tea and extract of Cordyceps militaris, and the dispersion-enhancing substance is a sugar alcohol. Based on dry weight, the proportion of vine tea extract in the composition is 1.5–2.5 parts by mass, and the proportion of Cordyceps militaris extract is 0.5–1.5 parts by mass. Preferably, the composition contains 0.8–1.2 parts by mass of vine tea extract and 0.8–1.2 parts by mass of Cordyceps militaris extract.

[0012] Furthermore, the vine tea extract contains 30% to 90% dihydromyricetin based on the dry weight fraction; the Cordyceps militaris extract contains 0.1% to 0.5% cordycepin.

[0013] Furthermore, the vine tea extract and the cordyceps militaris extract are extracts obtained using water as the extraction solvent.

[0014] In one specific embodiment, the vine tea extract is produced by extraction, filtration, concentration, drying and sieving; the Cordyceps militaris extract is produced by water extraction, filtration, concentration, drying and sieving.

[0015] Furthermore, the sugar alcohol is selected from at least one of erythritol, sorbitol, maltitol, isomalt, xylitol, lactitol and mannitol; erythritol is preferred.

[0016] Furthermore, the composition, based on dry weight, additionally comprises 0.1-1.5 parts by mass of a preparation made from Rosa roxburghii Tratt, preferably 0.8-1.2 parts by mass of the preparation made from Rosa roxburghii Tratt.

[0017] Furthermore, the preparation made from Rosa roxburghii Tratt contains 5% to 30% by weight of vitamin C.

[0018] Furthermore, the preparation made from Rosa roxburghii Tratt is obtained by drying Rosa roxburghii Tratt fruit juice.

[0019] In one specific embodiment, the preparation made from Rosa roxburghii Tratt is produced by processing Rosa roxburghii Tratt through fruit juice concentration, drying and sieving to create a preparation made from Rosa roxburghii Tratt.

[0020] Furthermore, the composition comprises, based on dry weight, an additional 0.1-0.5 parts by mass of a preparation made from sour cherry, preferably 0.1-0.2 parts by mass of the preparation made from sour cherry.

[0021] Furthermore, the preparation made from sour cherries contains 0.5% to 30% by weight of vitamin C.

[0022] Furthermore, the preparation made from sour cherries is obtained by drying the entire sour cherry.

[0023] In one specific embodiment, the preparation made from sour cherries is produced by mixing, drying, and sieving the entire sour cherry.

[0024] Furthermore, the composition contains additional excipients, the excipients comprising at least one substance selected from sodium bicarbonate, sodium carbonate, citric acid, food flavouring, fruit juice and thickeners.

[0025] A second aspect of the utility model consists in the provision of a solid drink, the active ingredients of which comprise the composition according to the first aspect.

[0026] The solid drink also includes effervescent tablets, dispersible tablets, granules and powders.

[0027] Furthermore, the solid beverage can be produced by processes such as crushing, sieving, weighing, granulating, drying, mixing and pressing the raw materials contained in the recipe.

[0028] In one specific embodiment, the daily intake is 23 to 28 g when taken once a day, if the composition is manufactured as a medicinal product or foodstuff and / or the solid drink is used to lower blood uric acid levels in hyperuricemia; preferably, the daily intake is 25 g.

[0029] The utility model applies the aforementioned technical solution and achieves the following technical effects compared to the prior art:

[0030] Through its specific weight ratios, the combined composition of vine tea extract, Cordyceps militaris extract, and sugar alcohol can effectively lower blood uric acid levels in subjects with hyperuricemia. This is of significant application in the production of foods and health-promoting products for lowering blood uric acid levels in individuals with hyperuricemia. The innovative addition of sugar alcohol, a Rosa roxburghii extract, and a sour cherry extract to the composition significantly improves its dispersibility. Whether the composition is in solid powder or granule form, the added sugar alcohol prevents moisture absorption and clumping, improves flowability, and accelerates dissolution and dispersal during brewing.This results in a higher dispersion rate for the product, further enhancing the aesthetics of the finished product and the ease of ingestion. EXPLANATION OF THE DRAWINGS Figure 1 shows a result diagram on the inhibitory effect of the vine tea extract on xanthine oxidase in vitro; Figure 2 shows a results diagram comparing the uric acid-lowering effect of the vine tea extract and the vine tea composition in individuals with hyperuricemia. EXAMPLES OF EXECUTION

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as they are commonly understood by those skilled in the art. In case of any discrepancy, this document, including its definitions, shall prevail. Preferred methods and materials are described below; however, methods and materials similar or equivalent to those described herein may also be used to carry out or test the utility model. The materials, methods, and examples disclosed herein serve only for illustrative purposes and are not to be construed as limiting.

[0032] For all value ranges mentioned in the present disclosure, all specific values ​​within this range, as well as any subranges bounded by two values ​​within this range, are disclosed. For example, for the range 1-20, the following are disclosed: specific values ​​such as 1, 2, 3, 3.5, 4.5, 10, 12, 15, 20, as well as subranges such as 1-5, 2-6, 3.5-7.5, and 15-20.

[0033] The experimental methods not specified in detail in the following examples are usually carried out according to national standards. The experimental materials not specified in the following examples are commercially available raw materials. The equipment used in the individual steps of the following examples is standard equipment. Where no applicable national standards exist, applicable international standards, customary conditions, or the manufacturer's recommended conditions are used. Unless otherwise stated, all parts are by weight and all percentages are by mass.

[0034] The utility model is explained below using an example. Example 1 - Recipe and manufacturing process of the composition

[0035] This example relates to the formulation and manufacturing process of a specific uric acid-lowering composition. 1. Formula composition:

[0036] The highly dispersible uric acid-lowering composition provided by the utility model comprises uric acid-lowering active ingredients and dispersion-enhancing substances, wherein the uric acid-lowering active ingredients comprise vine tea extract and Cordyceps militaris extract, and the dispersion-enhancing substances are sugar alcohols. Based on dry weight, the proportion of vine tea extract in the composition is 1.5–2.5 parts by mass, and the proportion of Cordyceps militaris extract is 0.5–1.5 parts by mass.

[0037] The vine tea extract is produced using water as the extraction solvent by extraction, filtration, concentration, drying, and sieving. The resulting vine tea extract contains 30 to 90 wt% dihydromyricetin. The Cordyceps militaris extract is produced using water as the extraction solvent by water extraction, filtration, concentration, drying, and sieving. The resulting Cordyceps militaris extract contains 0.1 to 0.5 wt% cordycepin.

[0038] Within the scope of the utility model, the extraction processes for the vine tea extract and the Cordyceps militaris extract are carried out according to standard methods; commercially available raw materials can also be obtained directly, which will not be discussed in detail here.

[0039] Furthermore, the sugar alcohol content, based on dry weight, is 5 to 20% of the composition.

[0040] Furthermore, the sugar alcohol is at least one selected from erythritol, sorbitol, maltitol, isomalt, xylitol, lactitol and mannitol; erythritol is preferred.

[0041] Furthermore, the composition contains, based on dry weight, 0.1–1.5 parts by mass of a Rosa Roxburghii preparation, preferably 0.8–1.2 parts by mass. The Rosa Roxburghii preparation is produced by concentrating the Rosa Roxburghii juice, drying, and sieving, and contains 5–30% by weight of vitamin C.

[0042] Furthermore, the composition contains, based on dry weight, 0.1–0.5 parts by mass of a sour cherry preparation, preferably 0.1–0.2 parts by mass. The sour cherry preparation is produced by mixing and drying whole sour cherries followed by sieving and contains 0.5–30% by weight of vitamin C.

[0043] Within the scope of the utility model, the manufacturing processes for the Rosa Roxburghii preparation and the sour cherry preparation are carried out according to standard methods; commercially available raw materials can also be obtained directly, which will not be discussed in detail here.

[0044] Furthermore, the composition contains additional excipients, the excipients comprising at least one substance selected from sodium bicarbonate, sodium carbonate, citric acid, food flavouring, fruit juice and thickeners.

[0045] In some embodiments, the composition can be processed into a solid beverage, for example into effervescent tablets, dispersible tablets, granules, powders and the like. 2. Manufacturing process

[0046] To prepare the composition or the festive beverage using the above-mentioned recipe, the following steps are carried out:

[0047] According to the above-mentioned recipe, the individual components are each weighed and then mixed evenly, thus obtaining the composition.

[0048] In the production of the festive beverage, the raw materials contained in the recipe are processed according to usual methods by crushing, sieving, weighing, granulating, drying, mixing, pressing and other processes. Example 2 - In vitro experiment on the xanthine oxidase inhibition activity of the vine tea extract

[0049] In this embodiment, the in vitro XOD inhibitory activity of the vine tea extract is measured using the experiment to inhibit xanthine oxidase (XOD) activity, expressed as the half-maximal inhibitory concentration (IC50). The specific procedure is as follows: 1. Reagents and equipment (1) Reagents: Vine tea extract prepared by extraction, filtration, concentration, drying, and sieving of vine tea; xanthine oxidase (X902417-500U, 50 U / mg); xanthine (X820565-25 g, ≥99.5%, molecular weight 152); allopurinol (A800424-25 g, 98%, molecular weight 136); PBS buffer solution (pH 7.5); hydrochloric acid solution (6 mol / L); DMSO, etc. (2) Equipment: micropipettes (10-100 µL, 100-1000 µL, 1-5 mL); centrifuge tubes (1.5 mL, 15 mL, 50 mL); volumetric flasks (25 mL); vortex mixer; thermostatically controlled air shaker; UV spectrophotometer, etc. 2. Experimental Procedure (1) Preparation of the solutions: PBS buffer solution: Solution A: Exactly 2.72 g of KH2PO4 are dissolved in 100 mL of distilled water to prepare a 0.2 M KH2PO4 solution. Solution B: Exactly 11.36 g of Na2HPO4 are dissolved in 400 mL of distilled water to prepare a 0.2 M Na2HPO4 solution. Solution A and solution B are mixed in a volume ratio (v / v) of 16:84 (56:294) to obtain a 0.2 M phosphate buffer solution with pH 7.5. This is then diluted 2.857-fold with distilled water to obtain a 70 mM phosphate buffer solution with pH 7.5. Xanthine oxidase solution (0.1 U / mL): 40 µL of a higher concentration xanthine oxidase solution (250 U / mL) are diluted to 10 mL with PBS solution and mixed thoroughly (Solution B, 1 U / mL, 10 mL). 1 mL of this mixture is then taken and mixed with 9 mL of PBS (Solution C, 0.1 U / mL, 10 mL), and stored until needed. Xanthine solution (150 µmol / L): Exactly 11.4 mg of xanthine are diluted to 25 mL with PBS buffer solution and sonicated for 15 min. 1.5 mL of this solution are then diluted to 30 mL, sonicated for a further 5 min, and stored until needed. Hydrochloric acid solution (1 mol / L):

[0050] A concentrated hydrochloric acid solution (6 mol / L) is diluted to 1 mol / L with a suitable amount of distilled water and stored until use. (2) Preparation of sample solutions of different concentrations:

[0051] Exactly one specific amount of vine tea extract sample is dissolved in 2% DMSO and diluted with PBS buffer solution to the appropriate concentration, so that sample solutions with concentrations of 250, 500, 750, 1000, 1250, 1500, 1750 µg / mL are prepared and stored until use. 3. Determination of XOD inhibitory activity(1) Experimental group setup: Negative group: 1.7 mL PBS buffer solution, 0.6 mL xanthine oxidase solution. Negative blank group: 2.3 mL PBS buffer solution. Sample group: 1 mL sample solution, 0.7 mL PBS buffer solution, 0.6 mL xanthine oxidase solution. Sample blank group: 1 mL sample solution, 1.3 mL PBS buffer solution. All groups are incubated for 15 min at 25 °C, then 1.2 mL of xanthine solution is added and the reaction is carried out for 30 min at 25 °C. After adding 0.5 mL of hydrochloric acid solution, the reaction is stopped and the absorbance is measured at 290 nm. (2) Data analysis:

[0052] The formula for calculating the XOD inhibition rate is as follows: Inhibition rate (%)=[((Anegative−Anegative−empty)−(Aprone−Aprone−empty)) / (Anegative−Anegative−empty)]×100%

[0053] In this context, Anegativ and Anegativ-lee are the absorption values ​​of the negative group and the negative-empty group respectively, Aprone and Aprone-lee are the absorption values ​​of the sample group and the sample-empty group respectively.

[0054] The IC50 is determined based on the inhibition rates of the samples at different concentrations. 50 -value calculated; the results are in Fig. depicted. 4. Experimental results

[0055] Out of Fig. It emerges that the IC50 The value of the vine tea extract is 395.4 µg / mL. This indicates that the vine tea extract exhibits a certain in vitro inhibitory effect on xanthine oxidase. Example 3 - In vitro experiment on the xanthine oxidase inhibition activity of the composition

[0056] In this embodiment, the composition from embodiment 1 serves as a test object to verify its in-vitro xanthine oxidase inhibitory activity. 1. The reagents, equipment and experimental procedure correspond to those in embodiment 2, only the mixing ratios of the sample components are different.

[0057] The Cordyceps militaris extract is produced by water extraction, filtration, concentration, drying, and sieving. The Rosa roxburghii preparation is obtained by juice concentration, drying, and sieving. The sour cherry preparation is produced by mixing and drying whole sour cherries, followed by sieving.

[0058] The exact composition of the samples in the experimental groups is shown in Table 1. Table 1 Composition of the samples in the experimental groups (weight ratio in dry state) Experimental group Vine tea extract Cordyceps militaris extract Rosa Roxburghii preparation Sour cherry preparation 1 1.5 0.5 1.5 0.1 2 2 0.5 0 0 3 2.5 0.5 1 0.5 4 1.5 1 1 0 5 2 1 1.5 0.5 6 2.5 1 0.5 0.1 7 1.5 1.5 0.5 0.5 8 2 1.5 1 0.1 9 2.5 1.5 0.5 0 10 2 1 1 0.1 11 1.5 0.8 0 0 12 2.5 1.5 0 0 13 2.5 1.5 0.1 0 14 2.5 1.5 1.5 0 15 2.5 1 1.5 0.1

[0059] The composition of the control samples is shown in Table 2. Table 2 Composition of the different control samples (weight ratio in dry state) Control group Vine tea extract Cordyceps militaris extract Rosa Roxburghii preparation Sour cherry preparation 1 1.3 0.3 0 0 2 2.7 1.7 0 0 3 1.3 0.3 0.05 0 4 2.7 1.7 1.7 0 5 1.3 0.3 0.05 0.7

[0060] The results of the in vitro xanthine oxidase inhibition activity of the experimental groups are shown in Table 3. Table 3 Results of the in vitro xanthine oxidase inhibition activity of different experimental groups Experimental group IC 50 (µg / mL) 1 480.60 2 551.21 3 505.19 4 481.98 5 475.87 6 515.40 7 469.57 8 482.47 9 505.02 10 462.90 11 522.72 12 517.49 13 514.75 14 486.88 15 493.78

[0061] The results of the in vitro xanthine oxidase inhibition activity of the control groups are shown in Table 4. Table 4 Results of the in vitro xanthine oxidase inhibition activity of different control groups Control group IC 50 (µg / mL) 1 553.62 2 515.30 3 549.12 4 484.63 5 502.50

[0062] Tables 3 and 4 show that the combination of the four raw materials vine tea extract, cordyceps militaris extract, Rosa roxburghii preparation and sour cherry preparation exhibits a significant inhibitory activity against XOD and that the four substances show a synergistic effect. Example 4 - Experiment to verify the uric acid-lowering effect

[0063] In this embodiment, the composition is prepared according to the formula from embodiment 1. This composition is administered to subjects with hyperuricemia to verify its uric acid-lowering effect in this group. Specifically, this involves the following steps: 1. Reagents and equipment: (1) Devices: BeneCheck PD-G001-3-P home uric acid meter and associated test strips; ROCHE Accu-CHEK® softclix home blood collection pen. 2. Experimental setup: Control group - Vine tea extract group: Vine tea extract Experimental group - Composition group (vine tea composition): Composition with the same amount of vine tea extract as in the vine tea extract group. The composition contains vine tea extract, Cordyceps militaris extract, and Rosa roxburghii preparation (in a dry mass ratio of 2:1:1.2).

[0064] The origin of the remaining extracts or preparations corresponds to that of embodiment 2. Other common fillers come from commercially available raw material suppliers. 3. Test subjects: Age: Adults (18-80 years); Number: Vine tea extract group (3 people); Vine tea composition group (6 people) Inclusion criteria: Concentration of uric acid in fingertip blood above 420 µmol / L; Rating index: Concentration of uric acid in fingertip blood in a fasting state; Dosage: 25 g after lunch, once daily; Study period: 5 weeks. Exclusion criteria for the subjects: ① The subjects took azathioprine, aspirin (>325 mg), atorvastatin, fenofibrate, losartan, thiazides, systemic corticosteroids, estrogens or oral contraceptives in the 2 weeks prior to or during the study. ② Serum creatinine > 3.0 mg / dL ③ GPT > 100 mg / dL ④ Pregnant or breastfeeding women ⑤ Individuals undergoing cancer chemotherapy or radiation therapy, as well as other individuals whom the study directors deem unsuitable for participation in the study. 4. Experimental procedure

[0065] Disinfect the fingertip area of ​​the subjects to be measured with alcohol. Blood is then always drawn from the same finger. The blood collection pen is activated at level 3. The first drop of blood is discarded, further drops of blood are drawn from the fingertip and measured using the appropriate uric acid test strips. Blood is drawn every Wednesday at 8:30 a.m. in a fasting state over a period of 5 weeks. 5. Experimental results

[0066] The decrease in uric acid concentration in the subjects compared to the respective baseline value five weeks after taking the composition or the same amount of vine tea extract is shown in Table 5 and Fig. depicted. Table 5: Uric acid concentrations of different experimental groups at different time points Number of weeks Vine tea extract group (%) Vine tea composition group (%) p-value 0 0 0 1 -4.2±4.9 7.5±6.5 0.033818 2 -9.6±14.9 6.8±12.4 0.443265 3 -0.1±19.8 5.8±7.3 0.153525 4 -2.5±4 11.2±5.6## 0.090560 5 -6.1±7.6 17.4±6.1***### 0.004878

[0067] Here, the following values ​​are used: ##: In the composition group compared to baseline, p < 0.01; ###: In the composition group compared to baseline, p < 0.005; ***: In the composition group compared to the vine tea extract group, p < 0.005.

[0068] From Table 5 and Fig.The results show that after five weeks of taking the compound, the uric acid concentration in the fingertip blood of the subjects decreased significantly compared to baseline, while no significant change was observed in the vine tea extract group compared to baseline. Furthermore, the decrease from baseline was more pronounced in the compound group than in the vine tea extract group. Therefore, the compound can lower the uric acid concentration of subjects more effectively than the vine tea extract alone. Example 4 - Experiment to improve the dispersibility and solubility of the composition using sugar alcohols

[0069] In this embodiment, the composition from embodiment 1 serves as the test object to investigate the influence of sugar alcohols on improving the dispersibility and solubility of the composition. This comprises the following steps: 1. Equipment and materials

[0070] Ingredients: Vine tea extract 12%, Cordyceps militaris extract 6%, Rosa roxburghii preparation 6%, sour cherry preparation 3%, erythritol (0-20%), sodium bicarbonate 6%, sweetener 0.5%, flavoring 3%, fruit powder 10%, maltodextrin (bulking agent) to bring to 100%. The difference between the various groups lies in the varying amount of erythritol added (0%, 5%, 10%, 20%). The aforementioned raw materials are processed into solid beverages A (0% erythritol), B (5% erythritol), C (10% erythritol), and D (20% erythritol) using main processes such as sieving, weighing, mixing, and filling.

[0071] Equipment: Measuring cylinder, pipetting aid (1000 mL), thermostatic magnetic stirrer, stopwatch, glass flask. 2. Experimental method

[0072] A 500 mL dry glass flask is used, exactly 250 mL of distilled water is added, and the mixture is magnetically stirred at a constant speed of 37 °C. Equal amounts of each of the solid beverages A, B, C, and D prepared above are weighed out and added to the flasks (one sachet per flask). The time from addition to complete dissolution of the powder, without any visible floating undissolved particles, is recorded to assess the dispersion and dissolution rates. The results are shown in Table 6. Table 6 Change in dispersion and dissolution time with and without the addition of sugar alcohol group Amount of sugar alcohol added Dispersing and dissolution time (s) A Sugar alcohol-free (0%) 73 B Sugar alcohol (5%) 55 C Sugar alcohol (10%) 28 D Sugar alcohol (20%) 25 3. Test results

[0073] Table 6 shows that the groups with a sugar alcohol addition of at least 10% exhibited faster dispersion and dissolution rates than the group without addition and the groups with a sugar alcohol addition of less than 10%. Furthermore, visual observation and sensory testing revealed that the visual appearance and taste of the dissolved solid beverages C and D were significantly improved with 10% and 20% sugar alcohol addition, respectively.

[0074] In summary, the inventive composition, which is prepared from vine tea extract, Cordyceps militaris extract, and sugar alcohol in a specific weight ratio, exhibits high inhibitory activity against xanthine oxidase and can effectively lower uric acid levels in subjects with hyperuricemia. The inventive addition of sugar alcohol, Rosa roxburghii preparation, and sour cherry preparation to the composition significantly improves its dispersibility and taste. When the composition is in the form of a solid powder or granules, the added sugar alcohol prevents moisture absorption and clumping, improves flowability, and accelerates dissolution and dispersion during brewing. This results in a higher dispersion rate and further enhances the aesthetics of the final product and its ease of administration.The substance has significant applications in the production of food and dietary foods for lowering uric acid levels in subjects with hyperuricemia.

[0075] Although certain features of the present utility model have been explained and described herein, the person skilled in the art will think of numerous variations, substitutions, modifications, and equivalents. Therefore, it is to be understood that the attached claims are intended to encompass all such variations and modifications that fall within the true spirit and scope of the present utility model.

Claims

A composition with high dispersibility for lowering uric acid levels, characterized in that the composition comprises a uric acid-lowering active ingredient and a dispersing agent, wherein the uric acid-lowering active ingredient contains vine tea extract and Cordyceps militaris extract and the dispersing agent is a sugar alcohol; based on the dry mass, the composition contains 1.5 to 2.5 parts by mass of vine tea extract and 0.5 to 1.5 parts by mass of Cordyceps militaris extract. Composition according to claim 1, characterized in that the vine tea extract contains 30-90 wt% dihydromyricetin based on dry weight; the Cordyceps militaris extract contains 0.1-0.5 wt% cordycepin. Composition according to claim 1, characterized in that the sugar alcohol is at least one substance selected from erythritol, sorbitol, maltitol, isomalt, xylitol, lactitol and mannitol. Composition according to claim 1, characterized in that the vine tea extract and the Cordyceps militaris extract are obtained using water as the extraction agent. Composition according to any one of claims 1 to 4, characterized in that the composition, based on the dry mass, further comprises 0.1 to 1.5 parts by mass of a Rosa Roxburghii preparation; and / or, based on the dry mass, the composition further comprises 0.1 to 0.5 parts by mass of a sour cherry preparation. Composition according to claim 5, characterized in that the Rosa Roxburghii preparation contains 5-30 wt% vitamin C; and / or the sour cherry preparation contains 0.5-30 wt% vitamin C. Composition according to claim 5, characterized in that the Rosa Roxburghii preparation is obtained by drying Rosa Roxburghii juice; and / or the sour cherry preparation is obtained by drying whole sour cherry fruits. Composition according to claim 1, characterized in that the composition further comprises excipients, wherein the excipients are at least one substance selected from sodium bicarbonate, sodium carbonate, citric acid, food flavouring, fruit juice and thickeners. Solid beverage, characterized in that the active ingredients of the solid beverage comprise the composition according to any one of claims 1 to 8. Solid beverage according to claim 9, characterized in that the solid beverage is in the form of an effervescent tablet, a dispersion tablet, granules or powder.

Images